CNN – In the days since Oxford University and AstraZeneca unveiled the results of the partnership’s Phase 3 Covid-19 vaccine trials, a growing number of questions have emerged.
The stated 70% average efficacy was significantly lower than the 94.5% to 95% reported by the other two leading candidates, Moderna and Pfizer, but the vaccine developed at England’s Oxford University is significantly cheaper than the others and, crucially, it would be far easier to transport and distribute in developing countries than its rivals since it does not need to be stored at freezing temperatures.
World on the Run | Jo Lee Magazine 